Insilico Medicine received a milestone payment of HKD 39 million from Menarini for the MEN2501 project, which has administered its first patient dose; Akeso Biopharma granted Jichuan Pharmaceutical exclusive commercialization rights for Yi Xi Ning.
Material Events:
Insilico Medicine (03696) received a milestone payment of HKD 39 million from Menarini, as the collaboration project MEN2501 administered its first patient dose.
Shoucheng Holdings (00697): Initial Public Offering of Shiaming Shares Listed on the Shenzhen Stock Exchange
Simcere Pharmaceutical (02096): Received a recent milestone payment under the overseas licensing option agreement with AbbVie for SIM0500.
Innoscience (02577) has successfully completed the critical design integration of its relevant products into Google's AI hardware platform and signed a compliant supply agreement.
United Laboratories (03933): UBT251 Injection for OSA indication has received tacit approval for clinical trials.
Akeso Biopharma (09926) has granted the exclusive commercialization rights of Yi Xi Ning to Jichuan Pharmaceutical.
Pharmaron (00867)'s self-developed innovative drug CMS-D017 capsule has been granted clinical trial approval for complement-mediated kidney diseases.
Operating performance:
Country Garden (02007) achieved contract sales attributable to shareholders of approximately RMB 2.21 billion in January 2026.
Nissin Foods (01475): Nissin Japan's China business segment reported an operating profit of 5.672 billion yen in the first three quarters, representing a year-on-year increase of 99.8%.
Natural Beauty (00157) announced a profit alert, expecting an annual net profit of approximately HKD 8 million to HKD 10 million, reversing the previous year's loss.
